Published online 12 June 2008
Haematologica, Vol 93, Issue 8, 1195-1202 doi:10.3324/haematol.12810
Copyright © 2008 by Ferrata Storti Foundation
Motoko Yamaguchi1 ,
Naoya Nakamura2 ,
Ritsuro Suzuki3 ,
Yoshitoyo Kagami4 ,
Masataka Okamoto5 ,
Ryo Ichinohasama6 ,
Tadashi Yoshino7 ,
Junji Suzumiya8 ,
Takuhei Murase9 ,
Ikuo Miura10 ,
Koichi Ohshima11 ,
Momoko Nishikori12 ,
Jun-ichi Tamaru13 ,
Masafumi Taniwaki14 ,
Masami Hirano5,15 ,
Yasuo Morishima4 ,
Ryuzo Ueda16 ,
Hiroshi Shiku1 ,
Shigeo Nakamura1
Haematologica, Vol 93, Issue 8, 1195-1202 doi:10.3324/haematol.12810
Copyright © 2008 by Ferrata Storti Foundation
Malignant Lymphomas |
De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients
1 Mie University Graduate School of Medicine, Tsu
2 Tokai University, Isehara
3 Nagoya University Graduate School of Medicine, Nagoya
4 Aichi Cancer Center, Nagoya
5 Fujita Health University School of Medicine, Toyoake
6 Tohoku University Postgraduate School of Medicine, Sendai
7 Okayama University Graduate School of Medicine and Dentistry, Okayama
8 Fukuoka University Chikushi Hospital, Fukuoka
9 Nishio Municipal Hospital, Nishio
10 St. Marianna Medical University, Kawasaki
11 Kurume University School of Medicine, Kurume
12 Kyoto University, Kyoto
13 Saitama Medical Center, Kawagoe
14 Kyoto Prefectural University of Medicine, Kyoto
15 Meijo University, Nagoya
16 Nagoya City University Medical School, Nagoya, Japan
Correspondence: Motoko Yamaguchi, M.D., Ph.D., Department of Hematology and Oncology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan. E-mail:waniwani{at}clin.medic.mie-u.ac.jp
Background: De novo CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL) is clinicopathologically and genetically distinct from CD5-negative (CD5–) DLBCL and mantle cell lymphoma. The aim of this retrospective study was to clarify the histopathological spectrum and obtain new information on the therapeutic implications of CD5+ DLBCL.
Design and Method: From 1984 to 2002, 120 patients with CD5+ DLBCL were selected from 13 collaborating institutes. We analyzed the relationship between their morphological features and long-term survival. The current series includes 101 patients described in our previous study.
Results: Four morphological variants were identified: common (monomorphic) (n=91), giant cell-rich (n=13), polymorphic (n=14), and immunoblastic (n=2). Intravascular or sinusoidal infiltration was seen in 38% of the cases. BCL2 protein expression in CD5+ DLBCL was more frequent than in CD5– DLBCL (p=0.0003). Immunohistochemical analysis in 44 consecutive cases of CD5+ DLBCL revealed that 82% of these cases (36/44) were non-germinal center B-cell type DLBCL. The 5-year overall survival rate of the patients with CD5+ DLBCL was 38% after a median observation time of 81 months. Patients with the common variant showed a better prognosis than those with the other three variants (p=0.011), and this was confirmed on multivariate analysis. Overall, 16 patients (13%) developed central nervous system recurrence.
Conclusions: Our study revealed the morphological spectrum of CD5+ DLBCL, found that the incidence of central nervous system recurrence in this form of lymphoma in high, confirmed that CD5+ DLBCL frequently expresses BCL2 protein and showed that it is mainly included in the non-germinal center B-cell type of DLBCL.
Key words: diffuse large B-cell lymphoma, CD5, histopathology, BCL2, central nervous system.
This article has been cited by other articles:
 |
|
 |
|
  P. Went, A. Zimpfer, A. Tzankov, and S. Dirnhofer CD5 expression in de novo diffuse large B-cell lymphomas Ann. Onc., April 1, 2009; 20(4): 789 - 790. [Full Text] [PDF]
|
|